Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sanofi And Ardelyx Sign Licensing Deal
by Rick Mullin
March 3, 2014
| A version of this story appeared in
Volume 92, Issue 9
Ardelyx has agreed to license its phosphate transport NaP2b inhibitor program to Sanofi for an undisclosed up-front sum. The deal includes development and regulatory milestones that could be worth $198 million. The inhibition of NaP2b should be useful for treating hyperphosphatemia, or elevated serum phosphate, in patients with chronic kidney disease, according to Ardelyx. Sanofi will have responsibility for development efforts. “Sanofi’s R&D and commercial capabilities in phosphate management are rivaled by no other company,” says Ardelyx CEO Mike Raab.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter